IQV | IQVIA Holdings Inc.

IndexS&P 500 P/E37.09 EPS (ttm)5.57 Insider Own0.88% Shs Outstand185.80M Perf Week2.59%
Market Cap37.88B Forward P/E17.28 EPS next Y11.96 Insider Trans-0.69% Shs Float184.29M Perf Month9.84%
Income1.05B PEG3.21 EPS next Q2.37 Inst Own91.10% Short Float / Ratio1.08% / 1.64 Perf Quarter4.73%
Sales14.49B P/S2.61 EPS this Y15.50% Inst Trans0.41% Short Interest2.00M Perf Half Y-0.53%
Book/sh31.93 P/B6.47 EPS next Y14.78% ROA4.20% Target Price243.89 Perf Year-6.40%
Cash/sh8.72 P/C23.70 EPS next 5Y11.55% ROE18.80% 52W Range165.75 - 249.11 Perf YTD0.83%
Dividend- P/FCF25.12 EPS past 5Y32.60% ROI8.20% 52W High-17.07% Beta1.39
Dividend %- Quick Ratio0.80 Sales past 5Y8.20% Gross Margin34.80% 52W Low24.64% ATR4.51
Employees87000 Current Ratio0.80 Sales Q/Q2.40% Oper. Margin12.20% RSI (14)63.15 Volatility1.74% 2.17%
OptionableYes Debt/Eq2.22 EPS Q/Q-8.80% Profit Margin7.30% Rel Volume0.80 Prev Close206.19
ShortableYes LT Debt/Eq1.99 EarningsApr 27 BMO Payout0.00% Avg Volume1.22M Price206.59
Recom1.70 SMA204.15% SMA505.34% SMA2000.64% Volume973,479 Change0.19%
Date Action Analyst Rating Change Price Target Change
Mar-17-23Initiated Truist Buy $265
Dec-06-22Initiated Cowen Outperform $251
Nov-17-22Downgrade Citigroup Buy → Neutral $275 → $245
Aug-25-22Initiated Credit Suisse Outperform $300
Jul-15-22Initiated SVB Leerink Outperform $256
May-24-22Initiated Guggenheim Buy $244
Apr-29-22Upgrade Piper Sandler Neutral → Overweight $231 → $255
Apr-25-22Downgrade Wells Fargo Overweight → Equal Weight $235
Aug-05-21Resumed Credit Suisse Outperform $272
Apr-16-21Upgrade Stephens Equal-Weight → Overweight $180 → $250
Jun-07-23 12:07PM
Jun-02-23 05:27AM
May-27-23 12:22PM
May-25-23 04:03AM
08:00AM Loading…
May-24-23 08:00AM
May-23-23 12:40PM
May-18-23 04:38PM
May-11-23 11:00AM
May-08-23 08:26AM
May-05-23 12:05PM
May-03-23 12:06AM
May-02-23 08:00AM
Apr-27-23 01:31PM
08:15AM Loading…
Apr-25-23 12:55PM
Apr-20-23 11:00AM
Apr-11-23 12:31PM
Apr-06-23 04:15PM
Mar-28-23 12:56PM
Mar-25-23 07:20AM
Mar-14-23 08:00AM
Mar-13-23 02:39PM
Mar-02-23 08:29PM
Mar-01-23 04:15PM
Feb-27-23 12:51PM
11:00AM Loading…
Feb-23-23 11:00AM
Feb-21-23 06:48PM
Feb-16-23 02:45PM
Feb-15-23 02:11PM
Feb-13-23 02:34PM
Feb-12-23 07:35AM
Feb-10-23 11:32AM
Feb-09-23 12:00PM
Feb-07-23 09:53AM
Feb-06-23 01:34PM
Feb-03-23 10:00AM
Jan-31-23 09:59AM
Jan-30-23 05:25PM
Jan-25-23 05:35PM
Jan-20-23 08:25AM
Jan-18-23 12:26PM
Jan-11-23 08:44AM
Jan-06-23 07:00AM
Jan-05-23 02:08PM
Jan-03-23 11:05AM
Jan-02-23 07:34AM
Dec-28-22 08:30AM
Dec-20-22 09:45AM
Dec-08-22 02:13PM
Dec-02-22 11:31AM
Nov-25-22 11:31AM
Nov-14-22 07:19AM
Nov-11-22 11:47AM
Nov-10-22 11:00AM
Oct-27-22 02:49PM
Oct-26-22 03:25PM
Oct-24-22 04:15PM
Oct-20-22 02:12PM
Oct-19-22 10:01AM
Oct-18-22 01:01PM
Oct-12-22 07:22AM
Oct-11-22 02:45PM
Oct-10-22 11:40AM
Oct-07-22 09:01AM
Oct-06-22 08:15AM
Oct-04-22 11:46AM
Oct-03-22 04:15PM
Sep-30-22 03:07PM
Sep-28-22 10:00AM
Sep-23-22 05:12PM
Sep-22-22 08:05AM
Sep-20-22 04:31PM
Sep-19-22 10:06AM
Sep-16-22 05:59PM
Sep-07-22 08:15AM
Sep-06-22 10:36AM
Sep-05-22 08:35AM
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and decentralized clinical trials, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was incorporated in 2016 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Knightly Kevin CSee RemarksJun 05Sale201.895,8201,175,0000Jun 07 05:31 PM
Knightly Kevin CSee RemarksMay 26Sale198.6611990May 31 09:29 PM
Knightly Kevin CSee RemarksFeb 16Sale225.614,4461,003,0681,973Feb 17 05:13 PM
Sherbet EricSee RemarksFeb 14Sale230.001,000230,00017,053Feb 15 05:58 PM